Utilities Associated with the Treatment of Growth Hormone Deficiency (GHD): A Time Trade-off (TTO) Study in the UK and Canada
Several aspects are associated with a significant impact on utilities for people with GHD and potential caregivers. Treatment options without injection pain, a time-consuming and complex injection process and daily injections are expected to result in higher health-related quality of life. These results may inform future economic evaluations and treatment choices.
Authors
- Gary Butler (ORCID: https://orcid.org/0000-0002-7094-1581)
- Lasse D. Jensen (ORCID: https://orcid.org/0000-0003-2338-357X)
- Susan Kirsch
- Cecilie Yssing (ORCID: https://orcid.org/0000-0002-3795-7071)
- Jonas Håkan‐Bloch
- Anna Okkels (ORCID: https://orcid.org/0000-0002-4039-8776)
Institutions
- Novo Nordisk (Denmark) (DK)
- Great Ormond Street Hospital (GB)
- Royal London Hospital (GB)
- Hospital for Sick Children (CA)
- Chr. Hansen (Denmark) (DK)
- SickKids Foundation (CA)
- University College London (GB)
Publication Details
- Journal
- Patient Related Outcome Measures
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2147/prom.s479705
- Primary Topic
- Adolescent and Pediatric Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk